BMS 962476

Drug Profile

BMS 962476

Alternative Names: BMS-962476; PCSK9 Adnectin

Latest Information Update: 02 May 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adnexus Therapeutics
  • Developer Adnexus Therapeutics; Bristol-Myers Squibb
  • Class Antihyperlipidaemics; Recombinant fusion proteins
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hypercholesterolaemia

Most Recent Events

  • 02 May 2016 No recent reports on development identified - Phase-I for Hypercholesterolaemia in USA (IV & SC)
  • 26 Feb 2013 Phase-I clinical trials in Hypercholesterolaemia in USA (SC & IV)
  • 26 Apr 2012 Preclinical trials in Hypercholesterolaemia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top